QIAGEN Acquires Genoox to Expand AI-Powered Genomics Portfolio

QIAGEN has announced the acquisition of Genoox, an Israeli provider of AI-powered genomic interpretation software, in a deal valued at $80 million. The acquisition includes Franklin, Genoox’s cloud-based platform, which will now join the QIAGEN Digital Insights (QDI) portfolio and enhance QIAGEN’s capabilities in clinical genomics.

Founded in 2014, Genoox developed Franklin to help small and mid-sized laboratories process complex next-generation sequencing (NGS) data, offering real-time, AI-driven clinical insights. The platform is widely used across more than 1,700 healthcare organizations in over 50 countries and has supported over 150,000 case interpretations to date. Its applications include diagnosing inherited diseases, informing cancer treatments, and guiding family planning decisions.

“This acquisition brings together two complementary strengths to better serve clinical testing laboratories,” said Thierry Bernard, CEO of QIAGEN. “Franklin’s AI-powered solution offers exciting opportunities for labs to rapidly identify the most clinically relevant insights and help improve patient outcomes.”

Genoox Co-founder and CEO Amir Trabelsi added, “Joining QIAGEN marks a major milestone in our mission to make genomic data more accessible and impactful.”

The integration of Franklin with QIAGEN’s robust genomic databases—including COSMIC, HGMD, and the QIAGEN Knowledge Base (QKB)—is expected to expand its interpretive power, reduce turnaround times, and increase scalability for clinical labs. It will also strengthen QIAGEN’s QCI Interpret and QCI Precision Insights offerings.

Under the terms of the agreement, QIAGEN will pay $70 million in cash, with an additional $10 million in milestone-based payments. The acquisition is expected to generate approximately $5 million in revenue in 2025 and have a neutral impact on adjusted EPS.